Wet Age-Related Macular Degeneration Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

Wet Age-Related Macular Degeneration Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight’s, “Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Insight, 2024,” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the Wet Age-Related Macular Degeneration pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Wet Age-Related Macular Degeneration therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Wet Age-Related Macular Degeneration Research. Learn more about our innovative pipeline today! @ Wet Age-Related Macular Degeneration Pipeline Outlook

 

Key Takeaways from the Wet Age-Related Macular Degeneration Pipeline Report

  • In October 2024:- Kodiak Sciences Inc.- A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Three-arm Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared with Intravitreal Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
  • In October 2024:- Hoffmann-La Roche- This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.
  • In October 2024:- Neuracle Genetics Inc.- A Phase 1/2a Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration. This is a Phase 1/2a, multicenter, open-label, dose escalation study to evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy, administered by subretinal injection in patients with active wAMD symptoms. The study will be conducted at approximately 5 sites in Canada and the USA.
  • DelveInsight’s Wet Age-Related Macular Degeneration pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Wet Age-Related Macular Degeneration treatment.
  • The leading Wet Age-Related Macular Degeneration Companies such as OliX Pharmaceuticals, Frontera Therapeutics, Kyowa Kirin, Boehringer Ingelheim, Clearside Biomedical, PanOptica, EyePoint Pharmaceuticals, Unity Biotechnology, AngioLab, Kinarus Therapeutics, Sylentis, Mabwell (Shanghai) Bioscience, Samsung Bioepis, Sandoz, Outlook Therapeutics, Molecular Partners, Sam Chun Dang Pharm, TOT Biopharm, and others.
  • Promising Wet Age-Related Macular Degeneration Pipeline Therapies in the various stages of development include Aflibercept (Eylea, BAY86-5321), Eyp-1901, NG101 AAV gene therapy, CMAB818, Lucentis®, RC28-E, Aflibercept, Ranibizumab, SCT510A, SCD411, Aflibercept, and others.

 

Stay informed about the cutting-edge advancements in Wet Age-Related Macular Degeneration Treatments. Download for updates and be a part of the revolution in cancer care @ Wet Age-Related Macular Degeneration Clinical Trials Assessment

 

Wet Age-related Macular Degeneration Emerging Drugs

  • RGX-314: REGENXBIO

RGX-314 is a one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for the formation of new leaky blood vessels and retinal fluid accumulation. RGX-314 is being developed as a potentially one-time treatment for wet AMD, diabetic retinopathy, and other additional chronic retinal conditions treated with anti-VEGF.

  • 9MW 0211: Mabwell (Shanghai) Bioscience

9MW 0211 is a recombinant anti-VEGF humanized monoclonal antibody obtained based on rabbit monoclonal antibody and humanized transformation technology, which is a category 1 therapeutic biological product. It can specifically bind to the most active VEGF-A in the VEGF family, block its binding to receptors on the surface of endothelial cells, reduce vascular permeability and block the formation and development of new blood vessels, and reduce the leakage caused by new blood vessels, so as to achieve the purpose of treating eye diseases related to neovascularization such as neovascular (wet) age-related macular degeneration. The drug is currently being evaluated in Phase II/III clinical trial to treat patients with wet-AMD.

  • SYL1801: Sylentis

SYL1801 is a chemically modified siRNA, engineered using Sylentis proprietary SirFinder, which inhibits the synthesis of Nrarp. It is administered as an eye drop solution to transcriptionally down-regulate the expression of Nrarp, a target different from those against which the usual anti-angiogenic therapies based on anti-VEGF agents are directed. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with wet AMD.

  • OLX10212: OliX Pharmaceuticals

OLX10212 is a novel cell penetrating asymmetric small interference RNA being developed by OliX Pharmaceuticals in Phase I stage of development for the treatment of wet-MAD. OLX10212 targets inflammation pathways that play a key role in the development of geographic atrophy (GA) and neovascular AMD.

 

Learn more about Wet Age-Related Macular Degeneration Drugs opportunities in our groundbreaking Wet Age-Related Macular Degeneration Research and development projects @ Wet Age-Related Macular Degeneration Unmet Needs

 

Wet Age-related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

 

Wet Age-Related Macular Degeneration Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

 

Discover the latest advancements in Wet Age-Related Macular Degeneration Treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Wet Age-Related Macular Degeneration Market Drivers and Barriers, and Future Perspectives

 

Wet Age-Related Macular Degeneration Companies and Therapies

  • Neuracle Genetics Inc.: NG101 AAV gene therapy
  • RemeGen Co. Ltd:- RC28-E
  • Outlook Therapeutics Inc.:- Bevacizumab/Ranibizumab

 

Scope of the Wet Age-Related Macular Degeneration Pipeline Report

  • Coverage- Global
  • Wet Age-Related Macular Degeneration Companies- OliX Pharmaceuticals, Frontera Therapeutics, Kyowa Kirin, Boehringer Ingelheim, Clearside Biomedical, PanOptica, EyePoint Pharmaceuticals, Unity Biotechnology, AngioLab, Kinarus Therapeutics, Sylentis, Mabwell (Shanghai) Bioscience, Samsung Bioepis, Sandoz, Outlook Therapeutics, Molecular Partners, Sam Chun Dang Pharm, TOT Biopharm, and others.
  • Wet Age-Related Macular Degeneration Pipeline Therapies- Aflibercept (Eylea, BAY86-5321), Eyp-1901, NG101 AAV gene therapy, CMAB818, Lucentis®, RC28-E, Aflibercept, Ranibizumab, SCT510A, SCD411, Aflibercept, and others.
  • Wet Age-Related Macular Degeneration Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Wet Age-Related Macular Degeneration Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Wet Age-Related Macular Degeneration Pipeline on our website @ Wet Age-Related Macular Degeneration Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Wet Age-related Macular Degeneration: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Wet Age-related Macular Degeneration– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. RGX-314: REGENXBIO
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. SYL1801: Sylentis
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. OLX10212: OliX Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Wet Age-related Macular Degeneration- Unmet Needs
  21. Wet Age-related Macular Degeneration- Market Drivers and Barriers
  22. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/